A Phase 1 interventional study of JTE-162 in Cryopyrin-associated Periodic Syndromes (CAPS), sponsored by Akros Pharma Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.
This study's enrollment of 5 is below the median of 19 across 27 interventional studies indexed under Cryopyrin-Associated Periodic Syndromes.
Browse Cryopyrin-Associated Periodic Syndromes studies →Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
First submitted before Akros Pharma Inc. became part of Shionogi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1 once daily for 2 Weeks
Drug: JTE-162
Tablets containing JTE-162
Change and percent change from baseline to end of treatment (EOT) in high-sensitivity C-reactive protein (hs-CRP)
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Serum amyloid A (SAA)
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Interleukin (IL)-6
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Key symptom score (KSS)
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Individual symptom score on Daily Health Assessment Form, Second Generation (DHAF2)
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Global assessments of disease activity on DHAF2
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Global CAPS symptom assessment by the Investigator
Time frame: 2 Weeks
Change and percent change from baseline to EOT in Individual CAPS symptom assessment by the Investigator
Time frame: 2 Weeks
Number of adverse events
Time frame: 4 Weeks
JTE-162 post-dose plasma concentrations on Day 1
Time frame: 1 Day
JTE-162 trough plasma concentrations on Days 2, 3 and 4, and at the Week 2 Visit (Day 15±2)
Time frame: Day 2, Day 3, Day 4 and Day 15±2
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cryopyrin-Associated Periodic Syndromes →